Article Information
History
- March 24, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Maria I. Edilova1,*,
- Jaclyn C. Law1,*,
- Safoura Zangiabadi2,
- Kenneth Ting1,
- Achire N. Mbanwi1,
- Andrea Arruda3,
- David Uehling4,
- Methvin Isaac4,
- Michael Prakesch4,
- Rima Al-awar4,5,
- Mark D. Minden3,
- Ali A. Abdul-Sater2,** and
- Tania H. Watts1,**,†
- 1Department of Immunology, University of Toronto, Toronto, ON, Canada
- 2School of Kinesiology and Health Science, Muscle Health Research Centre (MHRC), Faculty of Health, York University, Toronto, ON, Canada
- 3Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- 4Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada
- 5Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
- ↵†Corresponding author: Tania H. Watts, Department of Immunology, University of Toronto, Toronto, ON, Canada M5S 1A8; tel: 416-978-4551; tania.watts{at}utoronto.ca
Posted March 24, 2021.
The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia
